Holen Sie sich die Stockscreener-App
1.045
0.48%
-0.005
Schlusskurs vom Vortag:
$1.05
Offen:
$1.05
24-Stunden-Volumen:
155.65K
Relative Volume:
0.30
Marktkapitalisierung:
$64.40M
Einnahmen:
$248.00K
Nettoeinkommen (Verlust:
$-113.22M
KGV:
-0.5674
EPS:
-1.8416
Netto-Cashflow:
$-98.81M
1W Leistung:
+0.48%
1M Leistung:
-6.70%
6M Leistung:
-9.91%
1J Leistung:
-37.05%
1-Tages-Spanne:
$1.03
$1.055
1-Wochen-Bereich:
$1.03
$1.07
52-Wochen-Spanne:
$1.03
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.04 | 66.87M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
520.25 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.75 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.39 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.27 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
358.88 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics Inc (PLRX) Income Statement - TradingKey
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pliant Therapeutics Inc (PLRX) Cash Flow - TradingKey
Pliant Therapeutics Inc (PLRX) Balance Sheet - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics Inc (PLRX) Institutional Confidence - TradingKey
Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.080|Chg%:-0.010 - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.090|Chg%:+0.010 - TradingKey
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pliant Therapeutics Inc (PLRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pliant Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Pliant Therapeutics adds independent directors to strengthen R&D - TipRanks
Pliant Therapeutics (PLRX) director Robert Iannone submits initial Form 3 - Stock Titan
Pliant Therapeutics (PLRX) director files initial insider ownership statement - Stock Titan
Pliant Therapeutics (PLRX) awards 60,000 stock options to director Flavia Borellini - Stock Titan
[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event - Stock Titan
Pliant Therapeutics adds two directors with oncology expertise - Investing.com UK
Pliant Therapeutics appoints Flavia Borellini to board, strengthening executive leadership - Traders Union
Pliant Therapeutics adds two directors with oncology expertise By Investing.com - Investing.com Nigeria
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors - The Manila Times
Price to sales forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Price to earnings forward of Pliant Therapeutics, Inc. – FWB:9PT - TradingView
Price to book forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Enterprise value to revenue forward of Pliant Therapeutics, Inc. – FWB:9PT - TradingView
Enterprise value to revenue forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Price to earnings forward of Pliant Therapeutics, Inc. – TRADEGATE:9PT - TradingView
Pliant Therapeutics (PLRX) Stock Edges Lower, Holds Closely Above Key SupportAccumulation Line - dars.gov.et
Pliant Therapeutics (PLRX) Holds Steady at $1.17 as Traders Eye Key Support and Resistance LevelsVolume Dry Up - dars.gov.et
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – GETTEX:9PT - TradingView
Pliant Therapeutics Inc. (PLRX) Q1 2026 Earnings: Narrower Loss Sends Stock HigherTech Earnings Analysis - dars.gov.et
Pliant Therapeutics (PLRX) Edges Higher Amid Consolidation Near SupportPre-Earnings Momentum - dars.gov.et
Pliant Therapeutics Inc. (PLRX) Q1 2026 Earnings: EPS Beat Highlights Cost DisciplineSegment Revenue Breakdown - dars.gov.et
PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pliant Therapeutics (PLRX) Inches Higher Amid Ongoing Volatility: Key Levels to WatchMerger Arbitrage - dars.gov.et
Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
9PT Forecast — Price Target — Prediction for 2027 - TradingView
Pliant Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLRX) - TradingView
PLRX Forecast — Price Target — Prediction for 2027 - TradingView
Pliant Therapeutics (PLRX) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesManagement Guidance Update - DonanımHaber
Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14 - Stock Titan
Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000-share stock option grant - Stock Titan
Pliant (NASDAQ: PLRX) director awarded 70,000 stock options at $1.14 - Stock Titan
PLIANT THERAPEUTICS (PLRX) director granted 70,000 stock options at $1.14 - Stock Titan
Director Darren Cline receives 70,000 PLRX stock options at $1.14 strike price - Stock Titan
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pliant Therapeutics Inc-Aktie (PLRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
0.92%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):